US › Healthcare

Polaryx Therapeutics, Inc. Common Stock (PLYX)

US · Healthcare · Biotechnology

$2.23+1.83%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-2.5M

Profit YoY

+49.6%

EPS

$-0.05

EPS estimate

$-0.02

EPS came in at -0.05 against a street estimate of -0.02 — a miss of 150.0%.

Key statistics

Market cap

$115.1M

Forward P/E

0.0

P/B

46.08

Book value

$0.05

EPS (TTM)

$-0.14

52-week high

$48.91

52-week low

$1.86

50-day MA

$2.48

200-day MA

$4.47

Analyst view

with an average price target of $8.00.

Shareholding

Insiders

69.92%

Institutions

4.55%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	3.33%
Geode Capital Management, LLC	0.34%
Millennium Management LLC	0.26%
Vanguard Fiduciary Trust Co	0.21%
State Street Corp	0.12%
BlackRock Inc	0.08%
Northern Trust Corp	0.06%
Bank of America Corp	0.05%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Polaryx Therapeutics, Inc. Common Stock — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.